Trials / Conditions / Primary Systemic Amyloidosis

Primary Systemic Amyloidosis

18 registered clinical trials studyying Primary Systemic Amyloidosis.

Status	Trial	Sponsor	Phase
Completed	S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis NCT03499808	SWOG Cancer Research Network	Phase 2
Completed	Doxycycline to Upgrade Organ Response in Light Chain (AL) Amyloidosis Trial NCT02207556	Medical College of Wisconsin	Phase 2
Completed	Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Mye NCT01849783	Margarida Magalhaes-Silverman	Phase 2
Terminated	First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD NCT01728259	Barbara Ann Karmanos Cancer Institute	Phase 1
Active Not Recruiting	Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic NCT01199562	City of Hope Medical Center	—
Completed	Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic NCT01078454	National Cancer Institute (NCI)	Phase 3
Completed	Lendexal in Patients With Primary Systemic Amyloidosis (AL) Newly Diagnosed NCT01194791	PETHEMA Foundation	Phase 2
Completed	Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Canc NCT01053494	Wake Forest University Health Sciences	N/A
Completed	Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Light Chain Amyloid NCT01072773	Mayo Clinic	Phase 2
Completed	Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy NCT00890747	National Cancer Institute (NCI)	Phase 1
Completed	Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Depositi NCT00520767	Barbara Ann Karmanos Cancer Institute	Phase 2
Completed	High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in T NCT00536601	Roswell Park Cancer Institute	N/A
Terminated	Iododoxorubicin in Treating Patients With Primary Systemic Amyloidosis NCT00030381	National Cancer Institute (NCI)	Phase 1
Completed	Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction NCT00025415	National Cancer Institute (NCI)	Phase 1
Completed	Phase II Trial of Enbrel in Patients With Primary Systemic Amyloidosis NCT00224393	The Cleveland Clinic	Phase 2
Completed	Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Imm NCT00014235	Fred Hutchinson Cancer Center	N/A
Completed	Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporin NCT00006251	Fred Hutchinson Cancer Center	Phase 1 / Phase 2
Completed	Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenola NCT00112593	Fred Hutchinson Cancer Center	N/A